Several other analysts have also issued reports on the company. JPMorgan Chase & Co. boosted their price target on DexCom from $215.00 to $255.00 and gave the company an overweight rating in a report on Friday, December 20th. Oppenheimer boosted their price target on DexCom from $180.00 to $205.00 in a report on Thursday, November 7th. Piper Jaffray Companies reissued a buy rating and set a $230.00 price target on shares of DexCom in a report on Monday, December 16th. Canaccord Genuity boosted their price target on DexCom from $185.00 to $195.00 and gave the company a buy rating in a report on Thursday, November 7th. Finally, Robert W. Baird boosted their price target on DexCom from $195.00 to $240.00 and gave the company an outperform rating in a report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. DexCom currently has a consensus rating of Buy and an average price target of $209.80.
NASDAQ:DXCM opened at $231.62 on Friday. The stock has a 50-day simple moving average of $222.20 and a two-hundred day simple moving average of $179.58. DexCom has a 52-week low of $107.44 and a 52-week high of $242.14. The company has a debt-to-equity ratio of 1.41, a quick ratio of 5.26 and a current ratio of 5.63. The firm has a market capitalization of $21.46 billion, a PE ratio of -118.78 and a beta of 0.76.
In other news, CEO Kevin R. Sayer sold 10,000 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $157.50, for a total value of $1,575,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Patrick Michael Murphy sold 5,518 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $224.42, for a total value of $1,238,349.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,603 shares of company stock valued at $10,404,611. Corporate insiders own 0.88% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CSat Investment Advisory L.P. bought a new position in shares of DexCom in the second quarter worth about $31,000. Steward Partners Investment Advisory LLC lifted its position in shares of DexCom by 33.3% in the third quarter. Steward Partners Investment Advisory LLC now owns 280 shares of the medical device company’s stock worth $41,000 after buying an additional 70 shares in the last quarter. Assetmark Inc. lifted its position in shares of DexCom by 120.9% in the second quarter. Assetmark Inc. now owns 285 shares of the medical device company’s stock worth $43,000 after buying an additional 156 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of DexCom in the third quarter worth about $54,000. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of DexCom by 25.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,000 shares of the medical device company’s stock worth $149,000 after buying an additional 200 shares in the last quarter. 98.16% of the stock is owned by hedge funds and other institutional investors.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: Google Finance Portfolio
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.